What is the Logic behind Treating Some Heart Failure Patients without ACE Inhibitors and Beta-Blockers?Ebraheem Alskaf, Shadia Ahmed, Donna Barnett, Meg Warriner, Andrew Birchall, Victoria Watt and Abdallah Al-Mohammad*
Local audit of National Heart Failure Audit data 2012 in Sheffield Teaching Hospitals NHS Foundation Trust, UK
- *Corresponding Author:
- Abdallah Al-Mohammad
Heart Failure Services
Northern General Hospital
Harries Road, Sheffield, South Yorkshire, S5 7AU, UK
E-mail: [email protected]
Received date: June 24, 2014; Accepted date: July 29, 2014; Published date: August 05, 2014
Citation: Alskaf E, Ahmed S, Barnett D, Warriner M, Birchall A, et al. (2014) What is the Logic behind Treating Some Heart Failure Patients without ACE Inhibitors and Beta-Blockers? J Pharmacogenomics Pharmacoproteomics 5:137. doi: 10.4172/2153-0645.1000137
Copyright: © 2014 Alskaf E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: To obtain local data on the reasons why hospitalised heart failure patients are not being given a combination of beta-blockers (BB) and Angiotensin Converting Enzyme inhibitors (ACE –I).
Method: A survey was carried out of the heart failure patients discharged in the year 2012 from Sheffield Teaching Hospitals and reported to the National Heart Failure Audit who was not on ACE-I or BB. The main measures were the reasons for not giving those agents, and the use of alternative medications.
Results: The total number of our heart failure patients who were reported to the National Heart Failure Audit in 2012, and who were not on ACE-I or BB was 96 patients. Of these, 38 patients (40%) had heart failure with preserved ejection fraction (HFPEF), and 58 patients (60%) had left ventricular systolic dysfunction (LVSD).
Of the 58 patients with HF-LVSD, 25 patients did not have contraindications to either ACE-I or BB. However, 2 of them were on end of life care pathway (EOLCP) and thus were appropriately managed, this leaves 23/98 (23.5%) of overall patients managed inappropriately. Contraindications to or adverse effects from ACE-I or BB were encountered in 35/58 and 15/58 of the patients, respectively.
Conclusion: HFPEF is the main reason for not using BB and ACE-I in heart failure patients, followed by contraindications to these agents. ACE inhibitors had higher rate of adverse effects than beta blockers.